CO5080764A1 - Metodos para el tratamiento de enfermedades proliferativas - Google Patents

Metodos para el tratamiento de enfermedades proliferativas

Info

Publication number
CO5080764A1
CO5080764A1 CO98075842A CO98075842A CO5080764A1 CO 5080764 A1 CO5080764 A1 CO 5080764A1 CO 98075842 A CO98075842 A CO 98075842A CO 98075842 A CO98075842 A CO 98075842A CO 5080764 A1 CO5080764 A1 CO 5080764A1
Authority
CO
Colombia
Prior art keywords
substituted
alkyl
phenyl
substituents
halo
Prior art date
Application number
CO98075842A
Other languages
English (en)
Inventor
Walter R Bishop
Joseph J Catino
Ronald J Doll
Paul Kirschmeier
Liu Ming
Loretta L Nielsen
David L Cutler
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5080764(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5080764A1 publication Critical patent/CO5080764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un método para tratar enfermedades proliferas en un paciente que necesite dicho tratamiento, comprendido dicho tratamiento administrar concurrente o secuencialmente una cantidad eficaz de (1) un inhibidor de FPT, y (2) un agente antineoplástico y/o terapia de radicación; on la condición de que cuando el inhibidor FPT es un compuesto que tiene la fórmula <EMI FILE="98075842_1" ID="1" IMF=JPEG >Donde la línea de puntos representa un doble enlace opcional; X' es hidrógeno o halo; Y' es hidrógeno, -COOR' donde R´ es alquilo C1 a C12 o alquilo substituido, fenilo substituido, alquilarilo C7 a C 12 o arilalquilo substituido, 2- , 3- o 4-piperidilo o piperidilo N-substituido donde los substituyentes en dicho alquilo C1 a C12 substituido están seleccionados de amino y amino substituido, y los substituyentes en el amino substituido están seleccionados de alquilo C1 a C6, los substituyentes en dicho fenilo substituido y en dicha porción arilo substituida del alquilarilo C7 a C12 están seleccionados de alquilo C1 a C6 y halo y el substituyente en dicho piperidilo N-substituido es alquilo C1 a C4 o -SO2R' donde R' es alquilo C1 a C12 , fenilo, fenilo substituido, arilalquilo C7 a C12 o arilalquilo substituido donde los substituyentes en dicho fenilo substituido y en dicha porción arilo substituida del arilalquilo C7 a C12 están seleccionados de alquilo C1 a C6 y halo; y entonces el agente quimioterapéutico no está seleccionado del grupo que consiste en alcaloides vinca, epipodofillotoxinas, antibióticos de antraciclina, actinomicina D, plicamicina, puromicina, gramicidina D, taxol, colquicina, citocalasina B, emetina, maytansina, amsacrina.
CO98075842A 1997-12-22 1998-12-21 Metodos para el tratamiento de enfermedades proliferativas CO5080764A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
CO5080764A1 true CO5080764A1 (es) 2001-09-25

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075842A CO5080764A1 (es) 1997-12-22 1998-12-21 Metodos para el tratamiento de enfermedades proliferativas

Country Status (25)

Country Link
EP (1) EP1041985B1 (es)
JP (1) JP4502503B2 (es)
KR (1) KR100700907B1 (es)
CN (1) CN1129431C (es)
AR (1) AR017440A1 (es)
AT (1) ATE317697T1 (es)
AU (1) AU756762B2 (es)
BR (1) BR9814419A (es)
CA (1) CA2315693C (es)
CL (1) CL2007001889A1 (es)
CO (1) CO5080764A1 (es)
CZ (1) CZ298511B6 (es)
DE (1) DE69833509T2 (es)
DK (1) DK1041985T3 (es)
ES (1) ES2255196T3 (es)
HU (1) HUP0102473A3 (es)
IL (1) IL136462A0 (es)
MY (1) MY137303A (es)
NO (1) NO326832B1 (es)
NZ (1) NZ504928A (es)
PE (1) PE20000042A1 (es)
PT (1) PT1041985E (es)
SK (1) SK285584B6 (es)
TW (1) TW581763B (es)
WO (1) WO1999032114A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
US7034024B1 (en) * 1999-11-09 2006-04-25 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
US20030186925A1 (en) * 2000-02-29 2003-10-02 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397446A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
EP1267872A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2001064198A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
EP1365763B1 (en) * 2001-02-15 2008-11-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5416091A (en) * 1990-12-18 1995-05-16 Burroughs Wellcome Co. Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
ATE302613T1 (de) * 1995-08-09 2005-09-15 Banyu Pharma Co Ltd Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
CA2240846C (en) * 1995-12-22 2002-07-16 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
KR100561788B1 (ko) * 1996-03-12 2006-09-20 피지-티엑스엘 컴파니,엘.피. 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치
AU715604B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU714560B2 (en) * 1996-04-15 2000-01-06 Trustees Of The University Of Pennsylvania, The Sensitization of cells to radiation and chemotherapy
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
JP2000508335A (ja) * 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
WO1998032376A1 (en) * 1997-01-29 1998-07-30 Picker Medical Systems, Ltd. Predictive bolus tracking
ES2287974T3 (es) * 1997-02-18 2007-12-16 Canji, Inc. Terapia genica supresora de tumor y quimioterapia combinadas en el tratamiento neoplasmas.

Also Published As

Publication number Publication date
SK285584B6 (sk) 2007-04-05
NO20003229L (no) 2000-08-22
CN1284875A (zh) 2001-02-21
AR017440A1 (es) 2001-09-05
DE69833509D1 (de) 2006-04-20
EP1041985B1 (en) 2006-02-15
TW581763B (en) 2004-04-01
SK8982000A3 (en) 2001-04-09
HUP0102473A2 (hu) 2002-01-28
EP1041985A1 (en) 2000-10-11
NO326832B1 (no) 2009-02-23
NZ504928A (en) 2004-12-24
NO20003229D0 (no) 2000-06-21
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
PE20000042A1 (es) 2000-02-17
CL2007001889A1 (es) 2008-01-11
CN1129431C (zh) 2003-12-03
KR20010033452A (ko) 2001-04-25
DK1041985T3 (da) 2006-06-19
JP2001526224A (ja) 2001-12-18
AU756762B2 (en) 2003-01-23
KR100700907B1 (ko) 2007-03-29
WO1999032114A1 (en) 1999-07-01
HUP0102473A3 (en) 2003-07-28
PT1041985E (pt) 2006-07-31
DE69833509T2 (de) 2006-10-26
CZ298511B6 (cs) 2007-10-24
CZ20002236A3 (cs) 2001-04-11
CA2315693C (en) 2010-11-30
ES2255196T3 (es) 2006-06-16
AU1907299A (en) 1999-07-12
ATE317697T1 (de) 2006-03-15
IL136462A0 (en) 2001-06-14
MY137303A (en) 2009-01-30
JP4502503B2 (ja) 2010-07-14

Similar Documents

Publication Publication Date Title
CO5080764A1 (es) Metodos para el tratamiento de enfermedades proliferativas
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
TR199901669T2 (xx) Erkeklerdeki ereksiyon probleminin tedavisi i�in gerekli dozaj �ekilleri ve metod.
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
EA200000711A1 (ru) 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, СПОСОБ ПОЛУЧЕНИЯ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ, СОДЕРЖАЩИХ ЭТИ 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, И ИХ ПРИМЕНЕНИЕ ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
ATE212351T1 (de) Androsten-derivate
NZ509244A (en) Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
SE0003476D0 (sv) Compounds
GB9907571D0 (en) Compounds
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
EA200100214A1 (ru) Применение производных камптотецина с пониженной гастроинтестинальной токсичностью
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
EA200300516A1 (ru) Комбинация, включающая камптотецин и производные стильбена, для лечения рака
PE109199A1 (es) Enantiomeros de 4-[[(cianoimino) [(1,2,2-trimetilpropil)amino]metil]amino]-benzonitrilo
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
SE9500897D0 (sv) The pharmacological use of certain cystine derivatives
ATE210986T1 (de) Zubereitungen von 1,5-benzodiazepinderivaten mit cck-antagonistischen oder agonistischer wirkung mit enterischem überzug